HER2低表达乳腺癌的研究进展

Research progress in HER2-low breast cancer

乳腺癌(BC)已成为全球发病率最高的癌症,严重影响着女性的身心健康,是医学界的研究热点。BC的治疗已经迈入分子化时代。根据分子分型乳腺癌主要分为Luminal A型、Luminal B型、单纯人表皮生长因子受体2(HER2)阳性和三阴性乳腺癌(TNBC)。显然,HER2表达状态的正确判断对乳腺癌分型及治疗十分重要。随着研究的进一步加深,近期已有学者开始对乳腺癌中HER2表达状态的判读及乳腺癌分型提出了新的观点和看法。本文将结合目前的前沿观点及研究结果,介绍HER2低表达乳腺癌,以期为乳腺癌精准治疗及其进一步研究提供参考。

The latest statistics show that breast cancer(BC)has become the cancer with the highest incidence in the world,seriously affecting women′s physical and mental health,and has become a hot research topic in the medical field.Accordingly,its treatment has also entered the molecular era.According to its molecular classification,BC is mainly divided into Luminal A,Luminal B,simple human epidermal growth factor receptor 2(HER2)-positive and triple negetive breast cancer(TNBC).Obviously,correct judgment of HER2 expression status is very important for cancer typing and treatment of breast cancer.With the further development of research,some scholars have recently put forward new viewpoints and views on the interpretation of HER2 expression and cancer typing in breast cancer.This review will introduce the HER2-low breast cancer combined with the current frontier viewpoint and research findings,hoping to provide a reference for the precision treatment of breast cancer in the later stage and related further research.